8-K: BioCryst Reports Strong ORLADEYO Growth, Accelerates Path to Profitability

BioCryst Pharmaceuticals announced positive financial results for Q4 and full year 2023, driven by strong growth of ORLADEYO, and anticipates operating profit in 2024.

Summary

• BioCryst Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2023.
• ORLADEYO net revenue reached $90.9 million in Q4 2023 and $326.0 million for the full year 2023, representing a 30 percent year-over-year increase.
• The company expects ORLADEYO net revenue to be between $380 million and $400 million in 2024.
• BioCryst anticipates achieving operating profit in 2024 and approaching positive earnings per share (EPS) and positive cash flow in the second half of 2025.
• The company's total revenue for Q4 2023 was $93.4 million, compared to $79.5 million in Q4 2022.
• Full year 2023 total revenue was $331.4 million, up from $270.8 million in 2022.
• Net loss for Q4 2023 was $61.7 million, or $0.31 per share, compared to a net loss of $71.5 million, or $0.38 per share, for Q4 2022.
• The full year 2023 net loss was $226.5 million, or $1.18 per share, compared to a net loss of $247.1 million, or $1.33 per share, for 2022.
• Cash, cash equivalents, restricted cash and investments totaled $390.8 million as of December 31, 2023, compared to $443.9 million as of December 31, 2022.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, a clear path to profitability, and positive clinical data. While there are some negatives such as net losses and increased expenses, the overall tone is optimistic and suggests a positive trajectory for the company.

Positives

• ORLADEYO sales are growing strongly, with a 30 percent year-over-year increase in 2023.
• The company is on track to achieve operating profit in 2024 and approach positive EPS and cash flow in 2025.
• The number of patients using ORLADEYO is increasing, with a significant portion on paid product.
• New prescriber numbers for ORLADEYO are at a record high.
• R&D expenses have decreased due to the discontinuation of certain programs.
• ORLADEYO has received approvals and reimbursement in several new countries, expanding its global reach.

Negatives

• The company experienced a net loss of $61.7 million in Q4 2023 and $226.5 million for the full year 2023.
• Cash reserves decreased from $443.9 million at the end of 2022 to $390.8 million at the end of 2023.
• SG&A expenses increased significantly due to commercial expansion.
• There was a loss on extinguishment of debt of $29.0 million in 2023.

Risks

• The company's ability to successfully commercialize ORLADEYO could be impacted by various factors.
• The reduction in the size of the R&D organization could affect future product development.
• Government actions related to pricing could impact the company's financial performance.
• Clinical trials may not have positive results or may take longer than expected.
• The company's financial results may not be consistent with expectations.
• The company's ability to achieve profitability and positive cash flow may not meet management's expectations.

Future Outlook

BioCryst expects full year 2024 ORLADEYO net revenue to be between $380 million and $400 million, anticipates achieving operating profit in 2024, and is approaching positive EPS and positive cash flow in the second half of 2025. The company expects to be profitable on an EPS basis with positive cash flow for the full year 2026.

Management Comments

• Jon Stonehouse, president and chief executive officer of BioCryst, stated that the growth of ORLADEYO has accelerated the company's path to profitability.
• Charlie Gayer, chief commercial officer of BioCryst, noted that patients are switching to ORLADEYO due to its outstanding HAE attack control and tolerability.

Industry Context

This announcement reflects a positive trend in the rare disease pharmaceutical market, where companies with successful commercial products like ORLADEYO are seeing significant revenue growth and moving towards profitability. The focus on oral therapies also aligns with a broader industry trend towards patient-friendly treatment options.

Comparison to Industry Standards

• BioCryst's ORLADEYO is competing with other HAE treatments such as Takhzyro (lanadelumab) by Takeda and Haegarda (C1 esterase inhibitor) by CSL Behring. ORLADEYO's oral, once-daily administration is a key differentiator compared to the injectable options.
• The reported 30% year-over-year growth in ORLADEYO revenue is a strong performance compared to the average growth rates of other pharmaceutical companies in the rare disease space. For example, Takeda's Takhzyro reported a 15% growth in 2023.
• BioCryst's path to profitability is also notable, as many biotech companies in the rare disease space struggle to achieve profitability due to high R&D and commercialization costs. Companies like Alnylam and Sarepta Therapeutics are still working towards consistent profitability despite having approved products.
• The company's focus on reducing R&D expenses while increasing SG&A to support commercial growth is a common strategy for companies transitioning from development to commercialization. This is similar to what companies like Vertex Pharmaceuticals have done in the past.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and path to profitability.
• Employees may benefit from the company's growth and expansion.
• Patients will have increased access to ORLADEYO, a treatment for HAE.
• Creditors may view the company's financial outlook as positive.

Next Steps

• The company will continue to expand the commercialization of ORLADEYO.
• BioCryst will continue to invest in its pipeline of first-in-class or best-in-class molecules.
• The company will focus on achieving operating profit in 2024 and positive EPS and cash flow in 2025.
• BioCryst will continue to monitor the impact of the Inflation Reduction Act on revenue.

Key Dates

Keywords

ORLADEYO, BioCryst, Hereditary Angioedema, Pharmaceuticals, Financial Results, Revenue, Profitability, Net Loss, Clinical Trials, Drug Development